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1015-9584/Copyright ª 2015, Asian SuSummary Background/objective: One thousand liver transplantations have been performed
at the only liver transplant center in Hong Kong over a period of 22 years, which covered the
formative period of living donor liver transplantation. These 1000 transplantations, which
marked the journey of liver transplantation from development to maturation at the center,
should be educational. This research was to study the experience and to reflect on the impor-
tance of technical innovations and case selection.
Methods: The first 1000 liver transplantations were studied. Key technical innovations and sur-
gical therapeutics were described. Recipient survival including hospital mortality was
analyzed. Recipient survival comparison was made for deceased donor liver transplantation
and living donor liver transplantation indicated by hepatocellular carcinoma and other dis-
eases.
Results: Among the 1000 transplantations, 418 used deceased donor grafts and 582 used living
donor grafts. With the accumulation of experience, hospital mortality improved to < 2% in the
past 2 years. In the treatment of diseases other than hepatocellular carcinoma, living donor
liver transplantation was superior to deceased donor liver transplantation, with a 10-year
recipient survival around 90%.
Conclusion: Transplant outcomes have been improving consistently over the series, with a very
low hospital mortality and a predictably high long-term survival.
Copyright ª 2015, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.authors has any potential financial or nonfinancial conflicts of interest.
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The first 1000 liver transplants in Hong Kong 2031. IntroductionFigure 2 Adult recipient survival of transplants for in-
dications other than hepatocellular carcinoma.Liver transplantation (LT) was invented by Starzl et al in the
1960s1 and became a legitimate treatment in the 1980s.2
The impressive improvement in recipient outcomes was
the result of four areas of medical research. Cold storage of
livers in University of Wisconsin solution has extended the
graft preservation time3 and improved long-term graft
survival.4 Cyclosporine as the first calcineurin inhibitor used
is efficacious in reducing graft rejection.5 Prevention of
activation of hepatitis B virus (HBV) with passive immuno-
prophylaxis6 and then by antiviral agent lamivudine7 has
remarkably reduced HBV infection of grafts. Careful se-
lection of patients with hepatocellular carcinoma (HCC) for
LT has also contributed to a better rate of recipient long-
term survival.8
Asia entered this surgical arena only in the early 1990s.
In 1991, Hong Kong saw its first deceased donor LT (DDLT).
Two years after Strong et al9 of Brisbane performing the
first living donor LT (LDLT), Hashikura et al10 performed the
first adult LDLT in 1993 outside Australia. Japan was
instrumental in the development of LDLT, a long-waited
procedure for Asia where rates of organ donation from
the deceased have always been very low.11 Hong Kong had
its first LDLT conducted in 1993 for a child; in 1994, it had
its first adult LDLT.12 In 1996, the first adult LDLT using the
right liver placed Hong Kong on the world map of organ
transplantation.13 As one of the world’s leading centers in
LT, here we give an account of our first 1000 cases and
reflect on this experience. Only with a clear understanding
of the past can we advance further in our work.
Our first 1000 LTs started in 1991 and were accomplished
in October 2012. Among them, 418 were DDLTs and 582
LDLTs (Figure 1). There were 152 pediatric recipients. In
the treatment of non-HCC diseases, LDLT surpassed DDLT in
recipient survival, with a 10-year survival around 90%
(Figure 2), but it was outperformed by DDLT in theFigure 1 The first 1000 liver transplants at Queen Mary Hospita
yearly numbers of transplant types. DDLT Z deceased donor livertreatment of HCC, with a 10-year survival of around 70%
only (Figure 3). The hospital mortality of LT had been
reduced to < 3% since 2006 and was < 2% in 2011 and 2012
(up to October; Figure 4).
2. Innovations
2.1. Inclusion of the middle hepatic vein in the
right liver graft
In 1990, Tanaka et al14 used the right liver in a pediatric
LDLT to avoid a precarious anatomy of the left hepatic ar-
tery. In 1996, our center pioneered the use of the right liver
in adult LDLT to provide a graft adequate in size for the
recipient and to avoid small-for-size syndrome.13 As thel, the teaching hospital for The University of Hong Kong, with
transplant; LDLT Z living donor liver transplant.
Figure 3 Adult recipient survival of transplants for hepato-
cellular carcinoma.
204 S.C. Chan et al.right anterior section represents about half the volume of
the right liver, the middle hepatic vein was usually included
in the right liver graft to prevent congestion of segment 5
and segment 8,15 giving the recipient enough functional
liver. The donor should have a remnant liver at least 30% of
the original liver. Meticulous preservation of the segment
4b hepatic vein helps to minimize the risk of venous
congestion in segment 4.16 Even in the situation of a rather
low insertion of the vein into the middle hepatic vein, the
latter is divided caudal to the insertion, and merging of it to
the right hepatic vein is feasible.17
Implantation of the right and middle hepatic veins is
direct and requires no interpositional vascular graft.
Merging of the two hepatic veins into a single cuff using
venoplasty expedites vascular anastomosis.18 Following
anastomosis of the hepatic vein to the inferior vena cava
(IVC), patency of the IVC and hemodynamic stability can be
restored. Back flow of venous blood through the right portal
vein of the graft can be controlled with a bulldog vascularFigure 4 Yearly hospital mortality of liver tranclamp during portal vein anastomosis. As the graft has been
preserved in cold histidine-tryptophan-ketoglutarate solu-
tion with low potassium content, flushing of the graft
before clamp release is not necessary.19 The shortening of
cross-clamping time of the IVC by a median of 16 minutes
(unpublished data) also renders venovenous bypass
unnecessary.20
Conversance with hepatic venoplasty and direct anas-
tomosis between the IVC and the hepatic vein provides
convenience in sequential (or domino) LT, in which an
amyloid liver is used as a graft. An amyloid liver graft
usually does not contain the IVC, so the short hepatic veins
can first be merged as a single cuff, which is then anasto-
mosed to the IVC of the recipient.21
In the combined hearteliver transplant and the
following sequential LT our center performed a couple of
years ago, the single-cuffed hepatic vein of the amyloid
liver graft was, with the same principle, anastomosed to
the infrahepatic IVC obtained from the deceased heart and
liver donor on the back table for the recipient of the am-
yloid graft. The donor of the amyloid graft did not provide
the IVC as side-to-side IVC anastomosis was safer for her
because her newly implanted heart would not be able to
tolerate IVC cross-clamping.222.2. Monoagent nucleoside/nucleotide prophylaxis
without hepatitis B immunoglobulin
Passive immunization with parenteral hepatitis B immuno-
globulin significantly reduces the chance of HBV infection
of transplanted livers.23 However, the cost and the incon-
venience of such a regimen are well known. Lamivudine,
the first available orally administered effective agent
against HBV, has been used, usually in combination with
hepatitis B immunoglobulin.24 Our center pioneered lam-
ivudine monotherapy on patients transplanted for hepatitis
B,25 and the rate of hepatitis B recurrence from emergence
of mutants has been standing at 4e40%. Adoptive immunity
to HBV is sometimes found in our patients who havesplants at Queen Mary Hospital, Hong Kong.
Figure 5 The numbers of patients who would be saved with
every donor death in left liver and right liver LDLTs for various
indications. HCCZ hepatocellular carcinoma; HCVZ hepatitis
C; LDLT Z living donor liver transplant; Lt Z left; Rt Z right.
The first 1000 liver transplants in Hong Kong 205received liver grafts from donors positive for hepatitis B
surface antibodies. However, the production of hepatitis B
surface antibodies varies in incidence and duration after
LT,26 and the effect can only be beneficial and synergistic
with lamivudine. Patients who develop lamivudine-
resistant mutations can be given add-on adefovir.27
Entecavir, a much more potent nucleoside/nucleotide
analogue for the control of HBV, can also be used as a
monotherapy agent for LT recipients. It can bring about a
91% loss of hepatitis B surface antigens, with 98.8% having
undetectable HBV DNA.28 A long-term study of 362 LT pa-
tients with chronic hepatitis B on oral nucleoside/nucleo-
tide analogue therapy without hepatitis B immunoglobulin
demonstrated a virological relapse rate at 3 years of 0% for
entecavir versus 17% for lamivudine (p < 0.001), high-
lighting the importance of using a drug with a high barrier
to resistance. The regimen without hepatitis B immuno-
globulin resulted in excellent long-term survival, with an 8-
year survival of 83% without any HBV-related death.29
2.3. Donor interchange
Exchanging donated organs to overcome blood group in-
compatibility has taken place nearly a decade ago in kid-
ney transplantation.30 The issue, however, is more
complicated in LT, with two major problems. In LDLT, the
estimated mortality of donor left hepatectomy is 0.1% and
that of donor right hepatectomy is 0.5%,31 which are many
times higher than the 0.02% estimated mortality of living
kidney donation.32 For the recipient, LT is usually life-
saving. Graft failure and the lack of a timely retransplant
means death. Thus, donor interchange in LDLT carries a
higher donor risk and a higher recipient risk, but with a
bigger benefit.
Hwang et al33 of ASAN Medical Center, Seoul, South
Korea, and Soin of Medanta Institute, Gurgaon, India, have
been active in donor interchange in LDLT. In Hong Kong, we
conducted the first donor interchange in 2009. It helped out
a B-to-A pair and an A-to-B pair.34 Our second donor
interchange involved an altruistic donation from an O-to-AB
pair, helping an A-to-B pair.
3. Evolution
3.1. Acute liver failure
When first started, LDLT was for patients with acute liver
failure but without a deceased donor liver graft (DDLG).35
LDLT was considered undesirable in the West36 where the
supply of DDLGs is not as tight as that in the East. Our LDLT
program has been extended to serve patients with less ur-
gent needs, and acute and elective cases have comparable
survival outcomes after LDLT.37 As the failure of LDLT for
acute liver failure is a consequence of delay in treatment,38
a proactive approach to living donor workup is crucial.39
3.2. Minimum graft size requirement
The ratio of the left liver to the right liver is generally 1:3.
If the left liver has a bigger volume in relation to the totalliver volume, it is more likely to be adequate as a remnant
liver. A larger left liver also means a safer donor right
hepatectomy, and is a justification for a right liver LDLT.
The result would be an adequate right liver graft and an
adequate left liver remnant.
In the case where a donor has a very large body size in
relation to the recipient and thus a very large liver, a left
liver LDLT is most favorable. Although the workable mini-
mum graft size requirement is 35%, lowering of the
requirement with a tiny increase in the recipient mortality
rate should be the logical move for LDLT. This could give the
ratio of recipient benefit to donor risk a 5-fold increase. In
fact, right liver donors are five times more likely to die from
the donation than left liver donors (Figure 5). It has been
estimated that for every 5% reduction in the minimum graft
size requirement, twice as many left liver LDLTs could be
feasible.40
Extending the patient selection criteria for LDLT treating
HCC might result in a lower recipient success rate, but the
ratio of recipient benefit to donor risk can still be the same
if the donor risk is also lowered (Figure 6). Lowering of the
donor risk can be attained by using the left liver instead of
the right liver. Of course, any graft used must be of
adequate size for the recipient. The absence of significant
portal hypertension in patients is a factor favoring the
adoption of left livers. A high graft portal flow of over
400 mL/100 g/min calls for portal manometry by insertion
of a catheter via the inferior mesenteric vein, and a portal
pressure of over 20 mmHg calls for portal inflow modulation
with splenic artery ligation.41
3.3. Wait and transplant for HCC
DDLGs are a public resource while living donor liver grafts
are dedicated gifts. Judicious use of DDLGs is on a utili-
tarian ground whereas donor autonomy governs the use of
living donor liver grafts. Both kinds of grafts are precious
Figure 6 Equipoise between recipient survival and donor
mortality in left liver and right liver LDLTs for different in-
dications. HCCZ hepatocellular carcinoma; HCVZ hepatitis C;
LDLTZ living donor liver transplant; LtZ left; RtZ right.
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expected. The graft allocation policy is conservative for
HCC patients since DDLGs are scarce and survival outcomes
are excellent in DDLT recipients with indications other than
HCC. Our center has adopted a new policy since October
2009 to benefit HCC patients who are on the waiting list for
DDLT. Under the policy, patients whose HCC has remained
at  Stage 2 in the past 6 months are given extra points.
The test of time, although reliable, does have a price.42
Patients with less aggressive HCC, as demonstrated by the
waiting time, could have been transplanted at least 6
months earlier when the lesions were smaller and perhaps
fewer. Survival of these patients could only be better
because of a less advanced, perhaps also less aggressive,
disease.
3.4. Transplanting the resectable and resecting the
transplantable
Providing patients with the treatment that has the best
survival outcome is an easily understood policy. However,
from the health policy point of view, there are always
competitions for resources, and hence resources have to
be distributed according to specific criteria, one of which
has to be cost-effectiveness. In practice, a treatment is
cost-effective if it provides a survival benefit of world
standard.
An ideal transplant candidate with HCC and cirrhosis is a
patient in whom two or more tumors have been diagnosed
and for whom, in the absence of macrovascular and/or
lymph node invasion, secure R0 resection of a large tumor
cannot be guaranteed.43
LT is offered not only as a primary treatment but also to
two groups of patients who have undergone other treat-
ments in advance. The first group is patients whose HCCs
have been successfully downstaged using transarterial
chemoembolization. Downstaging tumors to a stage within
standard criteria, e.g., Milan44 or UCSF (University of Cal-
ifornia, San Francisco)45, can bring about good transplant
outcomes. These tumors are less aggressive as a result of
transarterial chemoembolization. The other group is pa-
tients failed by local ablative therapy, which typically uses
radiofrequency. This treatment policy selects patients
having tumors with more aggressive behavior for salvage
LT. Poor recipient outcomes are expected.46If the price paid by liver donors is disregarded, LT is the
best treatment for HCCs even if they are resectable, as long
as they are intrahepatic, because LT provides the best
survival outcome. Nevertheless, using DDLGs for this pur-
pose is out of the question since the benefit is to improve
survival by double. For every two DDLGs used, one could
have been spared should the patient have undergone liver
resection which turned out to be curative.
Donation of liver as a dedicated gift by a living donor is
not unreasonable if both the patient and the donor wish to
have the best recipient survival. However, one cannot
deny that one out of two donations from living donors is
unnecessary since one out of two patients can be cured
with liver resection.47 It could also be seen as using two
donors instead of one donor to save one patient with
resectable HCC. The doubling of donor risk or the cost paid
by the donors could be offset in a more favorable situation
if the left liver of the donor is adequate for the patient
who does not have established portal hypertension. This is
based on the fact that donor left hepatectomy is five times
safer than donor right hepatectomy. Similarly, for a pa-
tient with HCC beyond the standard criteria, the recur-
rence rate is higher. If a left liver is adequate for an LDLT,
the ratio of recipient benefit to donor risk is not worse
than that in a case using a right liver graft for HCC within
the standard criteria. This double equipoise requires
careful assessment of recipient survival and donor risk.48
HCC as a cancer does have different degrees of aggres-
siveness. HCC without vascular invasion often does not
metastasize within or outside the liver. Resection is
adequate and effective enough if the lesion is resectable.
More aggressive HCC often recurs within the liver, resulting
in poor disease-free survival. LT includes complete removal
of the native liver and thus precludes disease recurrence
within the remnant liver after hepatectomy. The most
aggressive and advanced HCC, with major vascular invasion
as a manifestation, will metastasize within and beyond the
liver. Treating such HCC using a precious liver graft, be it
from a deceased donor or from a living donor, is not
justifiable.
In an intention-to-treat analysis, the rate of salvage LT
was only 28%. When a follow-up plan is followed strictly,
the rate of recurrence with disease beyond standard
criteria for transplantation is particularly high. The recur-
rence of HCC to a stage beyond standard criteria is pre-
dictable if the patient has three of these four features:
microvascular invasion, satellite nodules, poor differentia-
tion of tumor cells, and liver cirrhosis. Preemptive LT
before recurrence should be considered.49 Nevertheless,
the transplant outcome would not be good if the tumor
cells are poorly differentiated.50 For unresectable HCCs, as
long as the lesions are not large and there are no numerous
or major vascular invasions, LT is acceptable and should
have a best survival outcome. It has been shown that
microvascular invasion per se does not compromise survival
as long as the disease is within the up-to-7 criteria.513.5. Rescue liver transplantation
We have performed four cases of rescue LDLT. With careful
recipient assessment and expeditious donor workup, all
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living donor is available, a cirrhotic HCC patient who would
have a remnant liver marginal in size and quality if liver
resection was conducted should not be denied LT. The
presence of microvascular invasion, even if confirmed with
histopathological examination, is not a contraindication to
transplantation if the disease is within the up-to-7
criteria.51 For more advanced HCC, LDLT can still be
acceptable if the tumor cells are not poorly differenti-
ated.50 However, given the uncertainty of recipient out-
comes and the possibility of post-transplant liver failure,
sometimes in addition to a disease stage too advanced for
transplantation, LDLT should be conducted only if the donor
is anxious to donate. Timeliness is crucial e transplantation
must be conducted before sepsis appears.
4. Reflections
4.1. Donor risks
The early postoperative outcomes of right liver donors are
markedly different from those of left liver donors as the
remnant liver of the former is only half the size of that of
the latter. On average, a left liver remnant is only one third
of the whole liver. When this ratio gets smaller, the post-
operative peak level of serum total bilirubin and interna-
tional normalized ratio get higher. Nevertheless, the
complication rates are similar among groups of donors with
different sizes of left liver remnant.53
It is the right of every potential living donor to have a
clear understanding of the potential or possible complica-
tions as well as the complication rate before consent to
donation is given. Although the time needed for a donor’s
liver function to return to normal seems to have no corre-
lation with complication, it is a recovery index. Nonethe-
less, this is usually not included in the discussion before
liver donation. One reason is the absence of studies doc-
umenting this. The other reason is the uncertainty of the
potential donor being able to understand this rather tech-
nical aspect of the surgery. However, potential donors need
to keep abreast of the latest knowledge about this major
surgery. When more than one volunteer are suitable for a
donation, this issue should be raised for all stakeholders to
discuss before deciding who is to be the donor. This is on
the basis that the volunteers have similar enthusiasm but
their remnant liver after donation would be different in
size. This principle is also applicable to factors like donor
age, body mass index, and physical condition. It is not
possible to give an accurate weight on each and every
factor, but the balance ought to be made by the donation
advocate.
At our center, the donation advocate is a transplant
surgeon who has no direct involvement in the management
or treatment of the patient, and thus has no conflict of
interest. Nevertheless, the advocate ought to have a good
knowledge of the chances of success and failure of the
proposed LDLT, as well as the 10-week mortality rate of
living right liver donors.54 The ratio of recipient benefit to
donor risk has to be estimated as accurate as possible so as
to enable the patient and the potential donor to come to an
informed decision.4.2. Safe donor surgery
It took 22 years for LDLT to come into clinical practice9
after DDLT had been successfully performed in 1967.51 It
then took another 7 years for a right liver LDLT to be
applied to adults.13 A prerequisite for an LDLT program is
the safe performance of donor hepatectomy. Most budding
centers in the late 1990s developed adult LDLT on a solid
base of an outstanding hepatobiliary surgery service. The
surgeons were already masters of liver surgery and thus
were competent at donor hepatectomy.54 This pattern was
most recognizable in Japan,55 Taiwan,56 Korea,57 and Hong
Kong.58 Some centers in Germany and France59 also had a
similar development. Centers in the United States also
caught up in the move later.
Although donor hepatectomy is by definition performed
on a normal liver, the standard of practice ought to be
superb to justify the conduct of this major surgery on a
healthy person who has absolutely no medical indication for
it. The logical answer to this is to provide the best facilities
and the best liver surgeons for the procedure. In the
formative years of donor hepatectomy, particularly donor
right hepatectomy, controversies arose over whether the
middle hepatic vein should be included in the graft or
preserved in the remnant liver. It is a matter of balance
between providing the most and the best for the recipient
and leaving the most and the best with the donor. Donor
hepatectomy mandates dedication, technical expertise,
and anatomical knowledge of the liver. Although surgeons
who carry out this procedure are experts, it is also a
learning process for them. Hence a steep learning curve is
observed at every transplant center.
For this procedure to be performed by newer surgeons,
the transfer of knowledge and skills ought to be smooth,
and no significant extra risk should be posed to the donors.
Delegation of the surgical duties, as well as the privilege, is
a gradual process and should be under guidance and
continuous auditing.
At our center, newer surgeons were included as opera-
tors in donor right hepatectomies after the first 200 cases.
They participated under the guidance of expert surgeons.
The involvement of newer surgeons was accompanied by a
temporary increase in blood loss and in operation time,
evident but well within the acceptable range. These two
factors and complication rate, the ultimate outcome
measure, are important parameters for assessment of the
standard of service. The complication rate did not increase
after the first 200 cases. We managed to maintain a high
standard of donor right hepatectomy while training a new
generation of surgeons.60
5. Conclusion
5.1. Accountable liver transplant service
Altruistic donor interchange enables an ABO-compatible
LDLT for an ABO-incompatible pair of donor and recipient.
The altruistic O and AB pair deserve a transplant service par
excellence; they should not bear any extra risks. Their
additional satisfaction from helping the other pair cannot
be denied yet is difficult to quantify. Technical successes in
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on organ donation. Ensuring excellent transplant results is
the least the LT community can do in promoting organ
donation, be it from the living or from the deceased.615.2. Ways ahead
In a rat model, the minimum regenerative threshold of
subtotal hepatectomy was a 10% remnant liver, with
attention to operative techniques and surgical therapeu-
tics.62,63 The minimum remnant liver size requirement for
donor survival after a major hepatectomy on a normal liver
is around 25%.64,65 However, an LDLT using a small-for-size
graft should produce results comparable with those ach-
ieved by liver resection, which include minimal injuries
resulting from ischemia, preservation, and reperfusion.
Translational studies followed by carefully conducted clin-
ical trials are the way to verify this hypothesis.
It should be considered whether to accept a slightly
lower rate of recipient survival when the rate of donor
mortality can be lowered significantly from 0.5% to 0.1%. In
right liver LDLT, the mortality is one in 200 and one in 50 for
donors and recipients, respectively, whereas the corre-
sponding ratios in left liver LDLT are one in 1000 and one in
50. It takes hundreds of donors to really see the difference
in donor mortality, and thus the different safety profiles, of
the two donor operations. Of course, multicenter studies
and surrogate parameters of donor morbidities enable
objective appraisal of the difference. It is also easy to
appreciate the more speedy recovery of recipients of liver
grafts that are adequate in size. This is particularly
attractive to patients who are very ill before trans-
plantation. In DDLT, a bad graft for a bad recipient is bad.
Thus, transplantation of a small-for-size graft to a very ill
patient is usually avoided. Our experience of transplanting
bad DDLGs to patients topping the transplant waiting list
has been a good lesson for such practice. It is the clear
concept of maximizing the ratio of recipient benefit to
donor risk that encourages the use of left liver grafts which
are smaller yet adequate.
LDLT is here to stay. Its cost and benefit vary according
to donor risk, recipient survival, and the availability of
DDLGs.66 Donor risk will not increase as long as the current
standard of care is maintained. Recipient survival has
improved with experience in surgery and surgical thera-
peutics, as well as improved patient selection. The pro-
portion and the number of LDLTs cannot be reduced
without an increase in DDLGs. When the ratio of recipient
benefit to donor risk is concerned, donor left hepatectomy
is preferable to donor right hepatectomy. The adoption of a
lower minimum graft size requirement without compro-
mising recipient survival will encourage the use of left liver
lobes as grafts in LDLT.Acknowledgments
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